The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval
Open accessAbstract
Aducanumab is the first FDA-approved amyloid-lowering immunotherapy for Alzheimer's disease. There is little real-world data to guide management of amyloid-related imaging abnormalities (ARIA), a potentially serious side-effect which requires surveillance with magnetic resonance imaging. We report our experiences in managing ARIA in patients receiving aducanumab at the Butler Hospital Memory and Aging Program during the year following FDA approval. We followed the Appropriate Use Recommendations for aducanumab to guide patient selection, detection, and management of ARIA (1). ARIA-E occurred in 6 out of 24 participants treated; all APOE-ε4 carriers. Treatment was discontinued in 4 cases of moderate-severe ARIA-E, temporarily held in 1 moderate case, and dosed through in 1 mild case (mean duration = 3 months, range, 1-6 months). No participants required hospitalization or high dose corticosteroids. Participants on anticoagulation were excluded and no macrohemorrhages occurred. These data support the measured approaches to treatment outlined in the Appropriate Use Recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lecanemab: Appropriate Use Recommendations
Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.30 · Cited by 961
Self-citation
Flagged first, then by citations
Research works printed but not linked: 12
- Cummings, 2022, Aducanumab: Appropriate Use Recommendations Update, Journal of Prevention of Alzheimer's Disease, 9, 221
- Budd Haeberlein, 2022, Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease, J Prev Alzheimers Dis, 9, 197
- Sevigny, 2016, The antibody aducanumab reduces Aβ plaques in Alzheimer's disease, Nature, 537, 50, 10.1038/nature19323 · DOI · Paper page
- Salloway, 2022, Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease, JAMA Neurol, 79, 13, 10.1001/jamaneurol.2021.4161 · DOI · Paper page
- 2023, 2023 Alzheimer's disease facts and figures, Alzheimers Dement
- van Dyck, 2023, Lecanemab in Early Alzheimer's Disease, N Engl J Med, 388, 142, 10.1056/NEJMoa2212948 · DOI · Paper page
- Lee, 2023, The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry, J Prev Alzheimers Dis, 10.14283/jpad.2023.12 · DOI
- Fazekas, 1987, MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging, AJR Am J Roentgenol, 149, 351, 10.2214/ajr.149.2.351 · DOI
- Hall, 2022, Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab, JAMA Neurol, 79, 87, 10.1001/jamaneurol.2021.3933 · DOI
- Dranitsaris, 2023, Therapeutic preference for Alzheimer's disease treatments: a discrete choice experiment with caregivers and neurologists, Alzheimers Res Ther, 10.1186/s13195-023-01207-8 · DOI
- VandeVrede, 2020, Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab, Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Regenhardt, 2020, Association Between Immunosuppressive Treatment and Outcomes of Cerebral Amyloid Angiopathy-Related Inflammation, JAMA Neurol, 77, 1261, 10.1001/jamaneurol.2020.1782 · DOI
Metadata
- Authors
- Howe, M. D., Britton, K. J., Joyce, H. E., Pappas, G. J., Faust, M. A., Dawson, B. C., Riddle, M. C., & Salloway, S. P.
- Affiliations
- Butler Hospital (US)
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-11
- Volume
- 10
- Issue
- 4
- Pages
- 765-770
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W4385560014
- Cited by
- 15
- References
- 1
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 10
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Journal of Prevention of Alzheimer s Disease (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG079241, P01AG051449)
- National Institute of Mental Health (R25MH101076)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- aducanumab, amyloid-related imaging abnormalities, ARIA-E, Alzheimer's disease, accelerated approval, APOE ε4 carriers, treatment discontinuation, real-world data, MRI surveillance
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Magnetic Resonance Imaging, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
